Ad Comms Update: Group Letter Submitted to FDA

PPMD is proud to help author and share the attached letter to Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research at the FDA. Along with CDMD at UCLA, the Duchenne Alliance, and The Race to Yes, PPMD is asking Dr. Woodcock to consider moving Sarepta’s Advisory Committee date to the same week in November as BioMarin’s. We have also asked the agency why the Ad Comms are separated by month and what this separation of time could mean for review. As a community we are doing everything we can to better understand last week’s decision by the FDA and we will update you with any news we receive.

Read the submitted letter:

Learn more

Views: 2442


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2022   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service